FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969577836> ?p ?o ?g. }

• W1969577836 endingPage "22596" @default.
• W1969577836 startingPage "22591" @default.
• W1969577836 abstract "Cross-linking MHC class II molecules human leukocyte antigen (HLA-DR) on the surface of THP-1 cells was found to induce their entry into the glycolipid-enriched membrane fraction of the plasma membrane. At the cellular level, this resulted in the synergistic co-aggregation of class II with cholera toxin, a marker of membrane rafts. The accompanying induction of intracellular protein tyrosine phosphorylation could be inhibited by treating cells with methyl-β-cyclodextrin, a drug that chelates membrane cholesterol and thereby disperses membrane rafts. Signaling could also be inhibited by treating cells with the Src-family kinase inhibitor PP1. Together, these results show that the induced association of class II molecules with membrane rafts can contribute to their aggregation on the cell surface and mediate an association with intracellular protein-tyrosine kinases. Cross-linking MHC class II molecules human leukocyte antigen (HLA-DR) on the surface of THP-1 cells was found to induce their entry into the glycolipid-enriched membrane fraction of the plasma membrane. At the cellular level, this resulted in the synergistic co-aggregation of class II with cholera toxin, a marker of membrane rafts. The accompanying induction of intracellular protein tyrosine phosphorylation could be inhibited by treating cells with methyl-β-cyclodextrin, a drug that chelates membrane cholesterol and thereby disperses membrane rafts. Signaling could also be inhibited by treating cells with the Src-family kinase inhibitor PP1. Together, these results show that the induced association of class II molecules with membrane rafts can contribute to their aggregation on the cell surface and mediate an association with intracellular protein-tyrosine kinases. The plasma membrane is known to contain distinct microdomains, which are enriched in glycosphingolipids, cholesterol, and specific membrane proteins (1Simons K. Ikonen E. Nature. 1997; 387: 569-572Crossref PubMed Scopus (8157) Google Scholar, 2Harder T. Simons K. Curr. Opin. Cell Biol. 1997; 9: 534-542Crossref PubMed Scopus (718) Google Scholar). Often referred to as membrane rafts, these domains can be distinguished from the rest of the plasma membrane by their relative insolubility in detergents and low buoyant density (3Brown D.A. Rose J.K. Cell. 1992; 68: 533-544Abstract Full Text PDF PubMed Scopus (2618) Google Scholar). They have been implicated in many cellular processes including membrane sorting in polarized cells (3Brown D.A. Rose J.K. Cell. 1992; 68: 533-544Abstract Full Text PDF PubMed Scopus (2618) Google Scholar, 4Dupree P. Parton R.G. Raposo G. Kurzchalia T.V. Simons K. EMBO J. 1993; 12: 1597-1605Crossref PubMed Scopus (404) Google Scholar, 5Fiedler K. Kobayashi T. Kurzchalia T.V. Simons K. Biochemistry. 1993; 32: 6365-6373Crossref PubMed Scopus (226) Google Scholar, 6Keller P. Simons K. J. Cell Biol. 1998; 140: 1357-1367Crossref PubMed Scopus (472) Google Scholar), endocytosis (7Deckert M. Ticchioni M. Bernard A. J. Cell Biol. 1996; 133: 791-799Crossref PubMed Scopus (145) Google Scholar, 8Parton R.G. Joggerst B. Simons K. J. Cell Biol. 1994; 127: 1199-1215Crossref PubMed Scopus (664) Google Scholar) and signal transduction from cell surface receptors (9Kabouridis P.S. Magee A.I. Ley S.C. EMBO J. 1997; 166: 4983-4998Crossref Scopus (318) Google Scholar, 10Xavier R. Brennan T. Li Q. McCormack C. Seed B. Immunity. 1998; 8: 723-732Abstract Full Text Full Text PDF PubMed Scopus (840) Google Scholar, 11Field K.A. Holowka D. Baird B. J. Biol. Chem. 1997; 272: 4276-4280Abstract Full Text Full Text PDF PubMed Scopus (325) Google Scholar, 12Rodgers W. Rose J.K. J. Cell Biol. 1996; 135: 1515-1523Crossref PubMed Scopus (286) Google Scholar, 13Stulnig T.M. Berger M. Sigmund T. Stockinger H. Horejsi V. Waldhausl W. J. Biol. Chem. 1997; 272: 19242-19247Abstract Full Text Full Text PDF PubMed Scopus (108) Google Scholar, 14Zhang W. Trible R.P. Samelson L.E. Immunity. 1998; 9: 239-246Abstract Full Text Full Text PDF PubMed Scopus (754) Google Scholar, 15Montixi C. Langlet C. Bernard A.-M. Thimonier J. Dubois C. Wurbel M.-A. Chauvin J.-P. Pierres M. He H.-T. EMBO J. 1998; 17: 5334-5348Crossref PubMed Scopus (560) Google Scholar). Different membrane-associated proteins can partition into the raft fraction to varying degrees; for example, the FcεR I is highly enriched within rafts (11Field K.A. Holowka D. Baird B. J. Biol. Chem. 1997; 272: 4276-4280Abstract Full Text Full Text PDF PubMed Scopus (325) Google Scholar, 16Stauffer T. Meyer T. J. Cell Biol. 1997; 139: 1447-1454Crossref PubMed Scopus (172) Google Scholar), whereas CD45 is excluded from them (12Rodgers W. Rose J.K. J. Cell Biol. 1996; 135: 1515-1523Crossref PubMed Scopus (286) Google Scholar). This partitioning can profoundly affect protein function, as has been demonstrated using site-directed mutagenesis to relocate the raft-associated signaling proteins Lck (9Kabouridis P.S. Magee A.I. Ley S.C. EMBO J. 1997; 166: 4983-4998Crossref Scopus (318) Google Scholar) and LAT (14Zhang W. Trible R.P. Samelson L.E. Immunity. 1998; 9: 239-246Abstract Full Text Full Text PDF PubMed Scopus (754) Google Scholar) within the fluid phase of the plasma membrane. Both of these molecules are targeted to membrane rafts by palmitoylation, a post-translational modification that is a good predictor of such targeting. To date, however, it has not proved possible to predict the partitioning characteristics of transmembrane proteins based on their primary sequence alone. It was therefore of interest to determine experimentally the degree to which major histocompatibility complex (MHC) 1The abbreviations used are: MHC, major histocompatibility complex; HLA, human leukocyte antigen; IFN-γ, interferon-γ; MβCD, methyl-β-cyclodextrin; GEM, detergent-insoluble membrane fraction; MES, 2[N-morpholino]ethane sulfonic acid; CT-FITC, cholera toxin B subunit, fluorescein isothiocyanate conjugate; PP1, 4-amino-5-(4chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine); PAGE, polyacrylamide gel electrophoresis; TCR, T cell receptor class II molecules partition into membrane rafts and the influence such partitioning has on class II function. MHC class II molecules are heterodimers composed of α and β polypeptides, both of which span the plasma membrane and have short cytoplasmic tails. High levels of class II are expressed on professional antigen-presenting cells, where they present processed exogenous antigen to CD4+ T cells. When recognition of the MHC-peptide complex by a specific T cell receptor (TCR) occurs, intracellular signals, including the induction of protein tyrosine phosphorylation, are transduced in the T cell through the TCR (17Klausner R. Samelson L. Cell. 1991; 64: 875-878Abstract Full Text PDF PubMed Scopus (329) Google Scholar) and in the antigen-presenting cells through the MHC class II molecules (18Corley R.B. LoCascio N.J. Ovnic M. Haughton G. Proc. Natl. Acad. Sci. U. S. A. 1985; 82: 516-520Crossref PubMed Scopus (42) Google Scholar, 19Cambier J.C. Lehmann K.R. J. Exp. Med. 1989; 170: 877-886Crossref PubMed Scopus (111) Google Scholar, 20Mooney N. Hivroz C. Ziai-Talebian S. Grillot-Courvalin C. Charron D. J. Immunogenet. (Oxf.). 1989; 16: 273-281Crossref PubMed Scopus (5) Google Scholar, 21Chatila T. Geha R.S. Immunol. Rev. 1993; 131: 43-59Crossref PubMed Scopus (54) Google Scholar, 22Andre P. Cambier J.C. Wade T.K. Raetz T. Wade W.F. J. Exp. Med. 1994; 179: 763-768Crossref PubMed Scopus (53) Google Scholar). MHC signaling has pleiotropic effects on antigen-presenting cell function, affecting antigen presentation (23Nabavi N. Freeman G.J. Gault A. Godfrey D. Nadler L.M. Glimcher L.H. Nature. 1992; 360: 266-268Crossref PubMed Scopus (292) Google Scholar), adhesion (24Mourad W. Geha R.S. Chatila T. J. Exp. Med. 1990; 172: 1513-1516Crossref PubMed Scopus (152) Google Scholar, 25Kansas G.S. Tedder T.F. J. Immunol. 1991; 147: 4094-4102PubMed Google Scholar, 26Ahsmann E.J. Boom S.E. Lokhorst H.M. Rijksen G. Bloem A.C. Eur. J. Immunol. 1997; 27: 2688-2695Crossref PubMed Scopus (10) Google Scholar), proliferation (19Cambier J.C. Lehmann K.R. J. Exp. Med. 1989; 170: 877-886Crossref PubMed Scopus (111) Google Scholar), apoptosis (27Newell M.K. VanderWall J. Beard K.S. Freed J.H. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 10459-10463Crossref PubMed Scopus (115) Google Scholar, 28Truman J.P. Garban F. Choqueux C. Charron D. Mooney N. Exp. Hematol. 1996; 24: 1409-1415PubMed Google Scholar), and cytokine release (29Trede N.S. Geha R.S. Chatila T. J. Immunol. 1991; 146: 2310-2315PubMed Google Scholar, 30Mourad W. Mehindate K. Schall T.J. McColl S.R. J. Exp. Med. 1992; 175: 613-616Crossref PubMed Scopus (94) Google Scholar, 31Altomonte M. Pucillo C. Damante G. Maio M. J. Immunol. 1993; 151: 5115-5122PubMed Google Scholar, 32Mehindate K. Thibodeau J. Dohlsten M. Kalland T. Sekaly R.P. Mourad W. J. Exp. Med. 1995; 182: 1573-1577Crossref PubMed Scopus (111) Google Scholar). The mechanism whereby class II initiates phosphotyrosine induction is currently unclear; surprisingly, the cytoplasmic tails of the class II polypeptides do not associate with any detectable tyrosine kinases (33Wade W.F. Davoust J. Salamero J. Andre P. Watts T.H. Cambier J.C. Immunol. Today. 1993; 14: 539-546Abstract Full Text PDF PubMed Scopus (75) Google Scholar), and the tails are in any case dispensable for the induction of tyrosine phosphorylation (22Andre P. Cambier J.C. Wade T.K. Raetz T. Wade W.F. J. Exp. Med. 1994; 179: 763-768Crossref PubMed Scopus (53) Google Scholar, 34Harton J.A. Van Hagen A.E. Bishop G.A. Immunity. 1995; 3: 349-358Abstract Full Text PDF PubMed Scopus (49) Google Scholar, 35Harton J.A. Bishop G.A. J. Immunol. 1993; 151: 5282-5289PubMed Google Scholar). Such signaling by class II is, however, critically dependent on the sequence of the highly conserved transmembrane regions of both the α and β polypeptides (33Wade W.F. Davoust J. Salamero J. Andre P. Watts T.H. Cambier J.C. Immunol. Today. 1993; 14: 539-546Abstract Full Text PDF PubMed Scopus (75) Google Scholar, 34Harton J.A. Van Hagen A.E. Bishop G.A. Immunity. 1995; 3: 349-358Abstract Full Text PDF PubMed Scopus (49) Google Scholar). This suggests that interactions between class II molecules and components of the plasma membrane are likely to be important for signaling. A precedent for intracellular signaling by proteins naturally lacking a cytoplasmic tail is afforded by glycosylphosphatidylinositol-linked surface molecules. Signaling by these molecules has been found to be dependent upon the integrity of membrane rafts (13Stulnig T.M. Berger M. Sigmund T. Stockinger H. Horejsi V. Waldhausl W. J. Biol. Chem. 1997; 272: 19242-19247Abstract Full Text Full Text PDF PubMed Scopus (108) Google Scholar, 36Edidin M. Stroynowski I. J. Cell Biol. 1991; 112: 1143-1150Crossref PubMed Scopus (103) Google Scholar, 37Stahl A. Mueller B.M. J. Cell Biol. 1995; 129: 335-344Crossref PubMed Scopus (182) Google Scholar, 38Romagnoli P. Bron C. J. Immunol. 1997; 158: 5757-5764PubMed Google Scholar), to which they are targeted by means of the glycosylphosphatidylinositol tail (1Simons K. Ikonen E. Nature. 1997; 387: 569-572Crossref PubMed Scopus (8157) Google Scholar). Signaling is thought to be dependent upon the aggregation of membrane rafts that accompany cross-linking of such raft-associated molecules. It is suggested that such aggregation facilitates the transactivation of raft-associated protein-tyrosine kinases and, hence, the initiation of intracellular signaling cascades (39Harder T. Scheiffele P. Verkade P. Simons K. J. Cell Biol. 1998; 141: 929-942Crossref PubMed Scopus (1048) Google Scholar). This led us to investigate whether membrane rafts play a role in the aggregation of MHC class II molecules and in facilitating an association protein tyrosine kinases. The human myelomonocytic cell line THP-1 was cultured in RPMI 1640 containing 5% fetal calf serum and antibiotics. To increase surface HLA-DR expression as required, cells at 106 ml−1 were cultured with human interferon (IFN)-γ (Genzyme, Cambridge, MA). Antibodies L243, CR3/43, and TU36, which recognize HLA-DR, were prepared as hybridoma supernatants. CR3/43 was affinity-purified using protein A-Sepharose from Amersham Pharmacia Biotech. 4G10, which recognizes phosphotyrosyl residues within peptides, was purchased from Upstate Biochemical Inc, Lake Placid, NY. HI30, which recognizes CD45, was from Pharmingen, San Diego, CA. Anti-caveolin was from Transduction Laboratories, Lexington, KY. Anti-Lyn rabbit antiserum was a gift of V. Tybulewicz (National Institute for Medical Research, UK). Horseradish peroxidase-conjugated anti-mouse and anti-rabbit antibodies for Western blotting were from Pierce. Texas Red conjugated goat anti-mouse and goat anti-rabbit antibodies for immunofluorescence staining were from Jackson Laboratories, Maine, PA. R-Phycoerythrin-conjugated rabbit anti-mouse antiserum, fluorescein isothiocyanate (FITC)-conjugated cholera toxin B subunit, methyl-β-cyclodextrin (MβCD), and cholesterol-loaded methyl-β-cyclodextrin were from Sigma Aldrich. 4-Amino-5-(4chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine) (PP1) was a gift from Y. Xu and R. Munshauer (BASF, Bioresearch Corp., Worcester, MA). To alter the cholesterol content of the plasma membrane, cells were washed three times in RPMI and resuspended at 107 cells ml−1 in the appropriate mix of 10 mm MβCD/cholesterol-loaded methyl-β-cyclodextrin for 30 min at 37 °C. The “percent cholesterol” refers to the percent cholesterol-loaded methyl-β-cyclodextrin in the mix. Cell were then washed into ice-cold RPMI. To stimulate cells, they were resuspended in L243 or CR3/43 supernatant or HI30 at 2 μg ml−1 in RPMI containing 5% fetal calf serum for 15 min on ice. Controls were resuspended in RPMI containing 5% fetal calf serum or 2 μg ml−1isotype-matched control antibody. Cells were then washed in cold RPMI, resuspended in rabbit anti-mouse antiserum for 5 min at 37 °C, and centrifuged at 15,000 × g for 30 s before lysis. Stimulation by pervanadate was carried out for 5 min at 37 °C by adding 100× stock solution created 15 min beforehand by mixing 50 mm Na3VO4 and 100 mmH2O2 in water. PP1 stock at 10 mmin Me2SO was used at a final concentration of 10 μm for 30 min at 37 °C to inhibit Src-family kinases. For analysis of whole cell protein, cells were lysed on ice for 15 min in a standard lysis buffer (25 mm Tris-HCl, pH 7.4, 150 mmNaCl, 100 mm Na3VO4 and 1 μg ml−1 each of chymostatin, leupeptin, and pepstatin) containing 1% Nonidet P-40 and cleared of insoluble matter by centrifugation at 20,000 × g for 30 min. For the enrichment of glycolipid-enriched membrane fractions (GEMs), cells were lysed in MNE buffer (25 mm MES, pH 6.5, 150 mmNaCl, 1 mm EDTA, 100 mmNa3VO4, and 1 μg ml−1 each of chymostatin, leupeptin, and pepstatin) containing 1% Triton X-100 for 30 min on ice. Lysates were mixed with an equal volume of 80% sucrose in MNE, placed at the bottom of a 40%, 30%, 5% discontinuous sucrose gradient, and centrifuged at 100,000 × g for 20 h. The insoluble GEM fraction was recovered from the 30%, 5% interface, mixed with an equal volume of MNE buffer, and pelleted at 20,000 × g for 30 min. GEM pellets were resuspended in Laemmli buffer including 5% β-mercaptoethanol, and soluble proteins in the 40% sucrose layer were mixed with an equal volume of 2 × Laemmli buffer. For detection of CD45, no β-mercaptoethanol was included. After heating to 95 °C for 5 min, samples were resolved by SDS-PAGE, and analyzed by standard Western blotting. Primary antibodies were used at 1 μg ml−1 or 1/1,000 for antisera, and secondary antibodies were used at 1/25,000. Staining was developed using Supersignal substrate from Pierce. For densitometric analysis, autorads were scanned using a Sharp 330 flatbed scanner, and results were analyzed using SharpTwain 1-D analysis software. THP-1 cells were pretreated with 10 mm MβCD for 30 min at 37 °C as appropriate, washed, then stained with primary antibody (neat L243 supernatant, purified HI30 at 2 μg ml−1 or isotype-matched antibody control) on ice for 15 min, washed once, stained with Texas Red conjugated goat anti-mouse antibody at 20 μg ml−1 on ice for 5 min, then warmed to 37 °C for a further 5 min. Cells were then washed in cold RPMI and fixed for at least 4 h in 3.7% paraformaldehyde. Fixed cells adhered to 3-aminopropyltriethoxysilane (TESPA) (Sigma)-coated coverslips were stained as appropriate with cholera toxin B subunit conjugated to fluorescein isothiocyanate (CT-FITC) at 1 μg ml−1 for 10 min before washing and mounting and viewed with an MRC 600 confocal microscope. For dual color analysis, cells were excited at 488 and 568 nm, with FITC (green) and Texas Red (red) fluorescence detected simultaneously. All images represent Z-series pileups of 15–18 transverse sections acquired at 0.5-μm intervals, from the top of a cell to its center. To test whether HLA-DR (MHC class II) is associated with the GEM fraction of the plasma membrane, THP-1 cells were treated with cross-linking antibodies as appropriate, lysed in MNE buffer containing 1% Triton X-100, and fractionated by discontinuous sucrose gradient centrifugation. Three discrete subcellular fractions were isolated: the GEMs from the 5%, 30% sucrose interface, soluble proteins from the 40% sucrose layer, and a pellet from the bottom of the tube. These fractions were analyzed by SDS-PAGE and Western blotting. HLA-DR molecules belonging to both the immature intracellular pool and the mature surface-bound pool were identified in the soluble fraction, the latter distinguished by their greater apparent molecular weight. No HLA-DR could be detected in the GEM fraction. However, when cells were treated with cross-linking anti-HLA-DR antibodies (either L243 or CR3/43 followed by a goat anti-mouse secondary antibody) before lysis, a significant fraction of the mature HLA-DR molecules were detected within the GEM fraction. (Fig.1 A). The immature, intracellular HLA-DR, being inaccessible to antibodies, showed no change in its distribution, although in some experiments a small fraction was constitutively associated with the GEM fraction, presumably reflecting an association with intracellular raft structures (3Brown D.A. Rose J.K. Cell. 1992; 68: 533-544Abstract Full Text PDF PubMed Scopus (2618) Google Scholar). HLA-DR could not be detected within the nuclear pellet under any circumstances (data not shown). As a control, we determined the fate of the transmembrane molecule CD45 following its cross-linking on the surface of THP-1 cells. In contrast to HLA-DR, CD45 could not be detected in the GEM fraction either before or after cross-linking, even when gels were heavily overloaded (Fig.1 B). This demonstrates that cross-linking with antibodyper se does not cause the indiscriminate entry of transmembrane proteins into the GEM fraction. Thus, cross-linking specifically enhances the partitioning of HLA-DR into GEMs. It is notable that, like other leukocytes (40Fra A.M. Williamson E. Simons K. Parton R.G. J. Biol. Chem. 1994; 269: 30745-33748Abstract Full Text PDF PubMed Google Scholar), THP-1 cells expressed no detectable caveolin (data not shown). Thus caveolae, which can form when caveolin associates with membrane rafts (41Fra A. Williamson E. Simons K. Parton R. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 8655-8659Crossref PubMed Scopus (529) Google Scholar), do not contribute to the GEMs isolated here (42Schnitzer J.E. McIntosh D.P. Dvorak A.M. Liu J. Oh P. Science. 1995; 269: 1435-1439Crossref PubMed Scopus (455) Google Scholar). To test whether the association of HLA-DR with membrane rafts affects its distribution on the surface of intact cells, THP-1 cells were used that had been induced to express high levels of HLA-DR by exposure to IFN-γ for 48 h. First, membrane rafts were revealed by incubating paraformaldehyde-fixed cells with the CT-FITC. This binds to GM1, a glycolipid concentrated within membrane rafts (43Parton R.G. J. Histochem. Cytochem. 1994; 42: 155-166Crossref PubMed Scopus (455) Google Scholar). Because CT-FITC has pentameric valency for GM1 (44Merritt E.A. Sarfaty S. van den Akker F. LqHoir C. Martial J.A. Hol W.G. Protein Sci. 1994; 3: 166-175Crossref PubMed Scopus (521) Google Scholar), it induced some aggregation of membrane rafts, giving a punctate staining pattern (Fig.2 a) similar to that reported elsewhere (39Harder T. Scheiffele P. Verkade P. Simons K. J. Cell Biol. 1998; 141: 929-942Crossref PubMed Scopus (1048) Google Scholar). Next, HLA-DR was cross-linked on cells before fixation using the primary antibody L243 and a Texas Red labeled goat anti-mouse secondary antibody. Large patches of HLA-DR formed within 5 min of exposure to the secondary antibody at 37 °C, which co-localized with CT-FITC (Fig. 2 b). This indicated that most cross-linked HLA-DR was associated with membrane raft aggregates. These aggregates were larger than those seen on the surface of control cells, suggesting that association with cross-linked HLA-DR contributed to membrane raft aggregation. As a control, the patching of CD45, shown above to be excluded from GEMs, was investigated. Typically of a surface-bound protein, CD45 also patched following cross-linking with antibodies. However, CD45 patches did not co-localize with CT-FITC, and their presence had no effect on the aggregation of membrane rafts (Fig. 2 c). To determine whether membrane rafts conversely contributed to the patching of HLA-DR, cells were pre-treated with MβCD, a drug that chelates cholesterol and thereby disrupts membrane rafts (1Simons K. Ikonen E. Nature. 1997; 387: 569-572Crossref PubMed Scopus (8157) Google Scholar). This had little effect on the distribution of CT-FITC on control cells (Fig.2 d), suggesting that GM-1 can be cross-linked by CT-FITC irrespective of membrane rafts. Treatment with MβCD did, however, reduce the size of HLA-DR patches as well as the degree of co-patching with CT-FITC (Fig. 2 e). This suggests that HLA-DR patches are qualitatively affected by their association with membrane raft aggregates. Consistently, the patching of CD45 was unaffected by MβCD (Fig. 2 f). When IFN-γ-treated THP-1 cells were exposed to cross-linking anti-HLA-DR antibodies, tyrosine phosphorylation of multiple proteins was induced, which was maximal within 5–10 min. Similar results were seen using three different antibodies, L243, CR3/43, and TU36; isotype-matched control antibodies induced no detectable tyrosine phosphorylation (data not shown). Qualitatively similar, but stronger, signaling was seen when the primary antibodies were hyper-cross-linked with a goat-anti-mouse secondary antibody. As a standard, cells were therefore stimulated by exposure to L243 on ice for 15 min, washed once in RPMI, then exposed to goat anti-mouse antibody for 5 min at 37 °C (Fig.3 A). To test whether phosphotyrosine induction by HLA-DR was dependent upon intact membrane rafts, cells were pretreated with MβCD to disperse the rafts. This inhibited the inducible tyrosine phosphorylation of all protein substrates detectable in total cell lysates by an average of 90% (Fig. 3, B and C). MβCD was not in itself toxic, since if it was partially loaded with cholesterol, its ability to inhibit phosphotyrosine induction was completely reversed (Fig. 3,B and C). Interestingly, excessive loading with cholesterol, which increased the size and protein content of the GEM fraction approximately 2-fold (data not shown), also inhibited the induction of tyrosine phosphorylation. This suggests that phosphotyrosine induction by HLA-DR is critically dependent upon the composition of the plasma membrane and that the cholesterol content of the plasma membrane of THP-1 cells is normally optimal for signaling. To test whether changes to the cholesterol content of cells compromised the integrity of phosphotyrosine signaling pathways, cells were stimulated with the phosphatase inhibitor pervanadate, which can activate intracellular tyrosine phosphorylation with no requirement for membrane-associated receptors. Pretreatment of cells with MβCD had no effect on their ability to respond to pervanadate, demonstrating that cholesterol modulation did not affect cell viability with respect to the ability to signal via phosphotyrosine induction (Fig.4). The above established that intact membrane rafts are required for the induction of all tyrosine phosphorylation events detectable in total cell lysates. Fractionation of HLA-DR-stimulated cells revealed that most inducible tyrosine phosphorylation occurred within the soluble fraction, although some occurred within the GEM fraction (Fig. 5 A). These events, undetectable in total cell lysates, could also be inhibited by MβCD (Fig. 5 A). There are therefore no detectable tyrosine phosphorylation events that are not inhibited by the disruption of membrane rafts, implying their involvement in the very earliest stages of HLA-DR induced phosphotyrosine induction. Following MβCD treatment, HLA-DR was undetectable in the residual GEM fraction (Fig.5 B), despite about 20% of its total protein remaining, as judged on gold-stained blots. This is consistent with the possibility that MβCD ablates phosphotyrosine induction by preventing the physical association of HLA-DR with residual membrane raft structures. The above suggested that tyrosine kinases physically associated with the inner leaflet of membrane rafts are likely to be involved in the initiation of HLA-DR-induced phosphotyrosine cascades. The prominent phosphorylated doublet enriched in the GEM fraction (Fig.5 A) was found by sequential Western blotting to have identical mobility to the Src-family tyrosine kinase Lyn (Fig.5 C). To test whether Src-family kinases (which are targeted to membrane rafts by N-terminal palmitoylation (45Resh M.D. Cell. 1994; 76: 411-413Abstract Full Text PDF PubMed Scopus (593) Google Scholar)) play a role in HLA-DR signaling, cells were treated with the Src-family specific kinase inhibitor PP1 (46Hanke J.H. Gardner J.P. Dow R.L. Changelian P.S. Brissette W.H. Weringer E.J. Pollok B.A. Connelly P.A. J. Biol. Chem. 1996; 271: 695-701Abstract Full Text Full Text PDF PubMed Scopus (1790) Google Scholar) prior to cross-linking HLA-DR with antibodies. This inhibited all inducible tyrosine phosphorylation events, including those within the GEM fraction, to below detectable levels (Fig. 6). Thus, Src-family kinase(s), most probably Lyn in THP-1 cells, are required for the induction of all detectable phosphotyrosine events induced by cross-linking HLA-DR. We have shown biochemically that cross-linking of HLA-DR induces its entry into GEMs, which are thought to be derived from membrane rafts. At the cellular level, this is accompanied by the co-aggregation of HLA-DR with membrane rafts. This contrasts with events following the cross-linking of CD45, which shows neither entry into GEMs nor co-aggregation with membrane rafts. It has been proposed elsewhere that raft aggregation could provide a mechanism to initiate signaling cascades through the clustering and transactivation of associated signaling molecules (39Harder T. Scheiffele P. Verkade P. Simons K. J. Cell Biol. 1998; 141: 929-942Crossref PubMed Scopus (1048) Google Scholar). Consistently, we found that the induction of intracellular tyrosine phosphorylation following HLA-DR cross-linking is entirely dependent upon the presence of intact membrane rafts, this being inhibited by MβCD. Using the specific inhibitor PP1, we have shown that raft-associated Src-family kinases are proximal mediators of HLA-DR phosphotyrosine induction. The activation of Src-family kinases has been shown to follow the aggregation of membrane rafts in other cell types (9Kabouridis P.S. Magee A.I. Ley S.C. EMBO J. 1997; 166: 4983-4998Crossref Scopus (318) Google Scholar, 11Field K.A. Holowka D. Baird B. J. Biol. Chem. 1997; 272: 4276-4280Abstract Full Text Full Text PDF PubMed Scopus (325) Google Scholar, 47Field K. Holowka D. Baird B. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 9201-9205Crossref PubMed Scopus (272) Google Scholar). A physical association between HLA-DR and raft-associated intracellular tyrosine kinases mediated by membrane rafts can explain several hitherto puzzling phenomena. First, class II can induce intracellular signaling in the absence of directly associated signaling molecules (33Wade W.F. Davoust J. Salamero J. Andre P. Watts T.H. Cambier J.C. Immunol. Today. 1993; 14: 539-546Abstract Full Text PDF PubMed Scopus (75) Google Scholar) and even in the absence of its cytoplasmic domains (34Harton J.A. Van Hagen A.E. Bishop G.A. Immunity. 1995; 3: 349-358Abstract Full Text PDF PubMed Scopus (49) Google Scholar). Second, the transmembrane sequences of both the α and β chains of class II molecules are critical for class II-mediated phosphotyrosine induction, which can be inhibited by point mutagenesis of these domains (34Harton J.A. Van Hagen A.E. Bishop G.A. Immunity. 1995; 3: 349-358Abstract Full Text PDF PubMed Scopus (49) Google Scholar). Interestingly, the native transmembrane domains exhibit an unusually high level of conservation across species and between different class II loci. Third, reports that class II can associate with the cytoskeleton, even when cytoplasmic tails have been removed, were based on the assumption that insoluble proteins are necessarily associated with the cytoskeleton (48Chia C.P. Khrebtukova I. McCluskey J. Wade W.F. J. Immunol. 1994; 153: 3398-3407PubMed Google Scholar). Class II in these instances is, however, likely to be associated with GEMs, which unless separated on the basis of density, co-pellet with the cytoskeleton. Under no conditions could we find HLA-DR associated with the dense, cytoskeletally enriched pellet that forms below the 40% layer of a discontinuous sucrose gradient. Finally, class II is reported to lose lateral mobility following multimerization (49Wilson K.M. Morrison I.E. Smith P.R. Fernandez N. Cherry R.J. J. Cell Sci. 1996; 109: 2101-2109Crossref PubMed Google Scholar), a characteristic of entry into membrane rafts (50Friedrichson T. Kurzchalia T.V. Nature. 1998; 394: 802-805Crossref PubMed Scopus (480) Google Scholar, 51Varma R. Mayor S. Nature. 1998; 394: 798-801Crossref PubMed Scopus (1031) Google Scholar). Our data suggest that cross-linking of HLA-DR leads to its association with membrane rafts, which are initially small and dispersed. Further cross-linking leads to the synergistic aggregation of membrane raft aggregates and HLA-DR patches. This process is required for the activation of Src-family tyrosine kinases, which are constitutively associated with the membrane rafts. Activation of raft-associated tyrosine kinases leads to the tyrosine phosphorylation of substrates within the soluble fraction of the cell, which are likely to be members of an extensive tyrosine kinase cascade. Further analysis will determine their individual identities and functions. This model raises the question as to how HLA-DR may be induced to enter membrane rafts following cross-linking. One possibility is that the transmembrane domains of the HLA-DR polypeptides are re-orientated within the plasma membrane when class II molecules are dimerized or undergo higher multimerization. Multimerization is suggested to occurin vivo when MHC/Ag+ and TCR interact at sufficiently high concentrations, as has been demonstrated in vitro (52Reich Z. Boniface J.J. Lyons D.S. Borochov N. Wachtel E.J. Davis M.M. Nature. 1997; 387: 617-620Crossref PubMed Scopus (204) Google Scholar). Such reorientation could lead to the partitioning of (multimerized) class II into the raft phase of the plasma membrane. Partitioning could also result from conformational changes induced in individual HLA-DR heterodimers following engagement of the TCR. Extrapolating our findings to the likely course of events in vivo, we suggest that HLA-DR normally occupies the fluid phase of the plasma membrane, where it has a high degree of lateral mobility and has no association with intracellular tyrosine kinases. When engaged by the T cell receptor, HLA-DR bearing specific antigen may be induced to associate with membrane rafts, linking it to raft-associated tyrosine kinases including members of the Src family. Engaged T cell receptor is known to be actively aggregated at the site of cell-cell contact, driven by an actin-dependent mechanism (53Dustin M.L. Shaw A.S. Science. 1999; 283: 649-650Crossref PubMed Scopus (207) Google Scholar, 54Wülfing C. Davis M.M. Science. 1998; 282: 2266-2269Crossref PubMed Scopus (536) Google Scholar). This may lead to the passive aggregation of bound class II bearing specific antigen on the surface of the antigen-presenting cells. Significantly, we found that treating THP-1 cells with cytochalasin D to disrupt the actin cytoskeleton had no effect on the induction of tyrosine phosphorylation by HLA-DR. Passive aggregation of HLA-DR may ensure that this process is dependent upon the specificity of the T cell receptor expressed by the interrogating T cell. Engaged, aggregated class II may then be laterally stabilized as the associated membrane rafts fuse together. Thus, only class II bearing cognate antigen for the specific TCR would be aggregated into a stable antigen presenting array. Raft aggregation may also facilitate the activation of raft-associated tyrosine kinases, as has been suggested elsewhere (39Harder T. Scheiffele P. Verkade P. Simons K. J. Cell Biol. 1998; 141: 929-942Crossref PubMed Scopus (1048) Google Scholar). We therefore suggest that membrane rafts may contribute to the function of MHC class II in two discrete ways: first, stabilizing localized aggregates, and second, mediating an association with intracellular tyrosine kinases. Future work will determine whether raft aggregation plays a critical role in antigen presentation by HLA-DR. We thank A. Bigley for support with confocal microscopy, V. Tybulewicz for anti-Lyn antiserum, and P. Kabouridis for his extensive advice and comments." @default.
• W1969577836 created "2016-06-24" @default.
• W1969577836 creator A5039090860 @default.
• W1969577836 creator A5068884310 @default.
• W1969577836 creator A5085384594 @default.
• W1969577836 date "1999-08-01" @default.
• W1969577836 modified "2023-09-26" @default.
• W1969577836 title "Intracellular Phosphotyrosine Induction by Major Histocompatibility Complex Class II Requires Co-aggregation with Membrane Rafts" @default.
• W1969577836 cites W1517168785 @default.
• W1969577836 cites W1528726881 @default.
• W1969577836 cites W1534119722 @default.
• W1969577836 cites W1542282362 @default.
• W1969577836 cites W1562084799 @default.
• W1969577836 cites W1593623110 @default.
• W1969577836 cites W1603104029 @default.
• W1969577836 cites W1621209507 @default.
• W1969577836 cites W1622169185 @default.
• W1969577836 cites W1630241876 @default.
• W1969577836 cites W1635401440 @default.
• W1969577836 cites W1945204933 @default.
• W1969577836 cites W1967230521 @default.
• W1969577836 cites W1972974591 @default.
• W1969577836 cites W1984150554 @default.
• W1969577836 cites W1988087702 @default.
• W1969577836 cites W1989531550 @default.
• W1969577836 cites W1990323187 @default.
• W1969577836 cites W2000764878 @default.
• W1969577836 cites W2004793282 @default.
• W1969577836 cites W2009808097 @default.
• W1969577836 cites W2023965621 @default.
• W1969577836 cites W2024203551 @default.
• W1969577836 cites W2032062053 @default.
• W1969577836 cites W2035599002 @default.
• W1969577836 cites W2040945595 @default.
• W1969577836 cites W2042704418 @default.
• W1969577836 cites W2047524663 @default.
• W1969577836 cites W2050465028 @default.
• W1969577836 cites W2066527693 @default.
• W1969577836 cites W2066591750 @default.
• W1969577836 cites W2068504553 @default.
• W1969577836 cites W2088955069 @default.
• W1969577836 cites W2090895449 @default.
• W1969577836 cites W2091707906 @default.
• W1969577836 cites W2094866428 @default.
• W1969577836 cites W2099593237 @default.
• W1969577836 cites W2109089280 @default.
• W1969577836 cites W2112605756 @default.
• W1969577836 cites W2115037258 @default.
• W1969577836 cites W2121936687 @default.
• W1969577836 cites W2124864045 @default.
• W1969577836 cites W2127444703 @default.
• W1969577836 cites W2133388060 @default.
• W1969577836 cites W2136449652 @default.
• W1969577836 cites W2138059603 @default.
• W1969577836 cites W2139846514 @default.
• W1969577836 cites W2145008974 @default.
• W1969577836 cites W2157829692 @default.
• W1969577836 cites W2159680966 @default.
• W1969577836 cites W2160659449 @default.
• W1969577836 cites W2188626161 @default.
• W1969577836 cites W95054676 @default.
• W1969577836 doi "https://doi.org/10.1074/jbc.274.32.22591" @default.
• W1969577836 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10428838" @default.
• W1969577836 hasPublicationYear "1999" @default.
• W1969577836 type Work @default.
• W1969577836 sameAs 1969577836 @default.
• W1969577836 citedByCount "109" @default.
• W1969577836 countsByYear W19695778362012 @default.
• W1969577836 countsByYear W19695778362013 @default.
• W1969577836 countsByYear W19695778362014 @default.
• W1969577836 countsByYear W19695778362015 @default.
• W1969577836 countsByYear W19695778362017 @default.
• W1969577836 countsByYear W19695778362019 @default.
• W1969577836 crossrefType "journal-article" @default.
• W1969577836 hasAuthorship W1969577836A5039090860 @default.
• W1969577836 hasAuthorship W1969577836A5068884310 @default.
• W1969577836 hasAuthorship W1969577836A5085384594 @default.
• W1969577836 hasBestOaLocation W19695778361 @default.
• W1969577836 hasConcept C104317684 @default.
• W1969577836 hasConcept C12554922 @default.
• W1969577836 hasConcept C15920480 @default.
• W1969577836 hasConcept C178790620 @default.
• W1969577836 hasConcept C185592680 @default.
• W1969577836 hasConcept C207936829 @default.
• W1969577836 hasConcept C41625074 @default.
• W1969577836 hasConcept C521977710 @default.
• W1969577836 hasConcept C55493867 @default.
• W1969577836 hasConcept C79879829 @default.
• W1969577836 hasConcept C86803240 @default.
• W1969577836 hasConcept C9132879 @default.
• W1969577836 hasConcept C95444343 @default.
• W1969577836 hasConceptScore W1969577836C104317684 @default.
• W1969577836 hasConceptScore W1969577836C12554922 @default.
• W1969577836 hasConceptScore W1969577836C15920480 @default.
• W1969577836 hasConceptScore W1969577836C178790620 @default.
• W1969577836 hasConceptScore W1969577836C185592680 @default.
• W1969577836 hasConceptScore W1969577836C207936829 @default.
• W1969577836 hasConceptScore W1969577836C41625074 @default.

• next